{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:43:58Z","timestamp":1790390638681,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T00:00:00Z","timestamp":1681689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T00:00:00Z","timestamp":1681689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum D\u00fcsseldorf. Anstalt \u00f6ffentlichen Rechts"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease in the western world. The excess mortality in NAFLD patients is strongly related to extrahepatic comorbidities. Recently, an association between NAFLD and chronic kidney disease (CKD) has been reported in various populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Based on the IQVIA Disease Analyzer database, this retrospective study examined two cohorts from Germany matched for sex, age, index year, annual visit frequency, hypertension, and diabetes, including 92,225 patients with and without NAFLD. The incidence of CKD was assessed as a function of NAFLD using Cox regression models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 92,225 NAFLD patients as well as 92,225 patients without NAFLD were included into analyses. CKD was diagnosed in 19.1% vs. 11.1% of patients with and without NAFLD within the 10\u00a0years observation period (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Cox regression confirmed a significant association between NAFLD and CKD with a hazard ratio (HR) of 1.80 (95%CI: 1.73\u20131.86,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Subgroup analyses revealed that this association was most pronounced in the age group of 18 to 50\u00a0years (HR: 2.13, 95%CI: 1.91\u20132.37,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and among female NAFLD patients (HR 1.85, 95%CI: 1.76\u20131.95,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The results of this study confirm a significantly increased risk of developing CKD in a large, real-world cohort of adult NAFLD patients in Germany. Interdisciplinary care of NAFLD patients, which is currently gaining importance worldwide, should be considered to include systematic measures for prevention and\/or early detection of CKD with the aim of minimizing long-term renal complications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40001-023-01114-6","type":"journal-article","created":{"date-parts":[[2023,4,16]],"date-time":"2023-04-16T23:45:54Z","timestamp":1681688754000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Non-alcoholic fatty liver disease (NAFLD) is associated with an increased incidence of chronic kidney disease (CKD)"],"prefix":"10.1186","volume":"28","author":[{"given":"Christoph","family":"Roderburg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Krieg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Krieg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00fcnevver","family":"Demir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Luedde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel","family":"Kostev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven H.","family":"Loosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,17]]},"reference":[{"issue":"4","key":"1114_CR1","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","volume":"69","author":"C Estes","year":"2018","unstructured":"Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016\u20132030. J Hepatol. 2018;69(4):896\u2013904.","journal-title":"J Hepatol"},{"issue":"10","key":"1114_CR2","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1016\/j.cgh.2018.12.016","volume":"17","author":"Y Huber","year":"2019","unstructured":"Huber Y, Boyle M, Hallsworth K, Tiniakos D, Straub BK, Labenz C, et al. Health-related quality of life in nonalcoholic fatty liver disease associates with hepatic inflammation. Clin Gastroenterol Hepatol. 2019;17(10):2085-92.e1.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"1114_CR3","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1002\/hep.29546","volume":"67","author":"AM Allen","year":"2018","unstructured":"Allen AM, Therneau TM, Larson JJ, Coward A, Somers VK, Kamath PS. Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: a 20 year-community study. Hepatology. 2018;67(5):1726\u201336.","journal-title":"Hepatology"},{"issue":"3","key":"1114_CR4","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.jhep.2020.04.030","volume":"73","author":"O Glass","year":"2020","unstructured":"Glass O, Filozof C, Noureddin M, Berner-Hansen M, Schabel E, Omokaro SO, et al. Standardisation of diet and exercise in clinical trials of NAFLD-NASH: recommendations from the Liver Forum. J Hepatol. 2020;73(3):680\u201393.","journal-title":"J Hepatol"},{"issue":"1","key":"1114_CR5","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202\u20139.","journal-title":"J Hepatol"},{"issue":"6","key":"1114_CR6","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1136\/gutjnl-2017-313884","volume":"66","author":"LA Adams","year":"2017","unstructured":"Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017;66(6):1138\u201353.","journal-title":"Gut"},{"issue":"2","key":"1114_CR7","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/apt.14112","volume":"46","author":"S Sookoian","year":"2017","unstructured":"Sookoian S, Pirola CJ. Systematic review with meta-analysis: risk factors for non-alcoholic fatty liver disease suggest a shared altered metabolic and cardiovascular profile between lean and obese patients. Aliment Pharmacol Ther. 2017;46(2):85\u201395.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"1114_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-019974","volume":"8","author":"XY Hu","year":"2018","unstructured":"Hu XY, Li Y, Li LQ, Zheng Y, Lv JH, Huang SC, et al. Risk factors and biomarkers of non-alcoholic fatty liver disease: an observational cross-sectional population survey. BMJ Open. 2018;8(4): e019974.","journal-title":"BMJ Open"},{"issue":"13","key":"1114_CR9","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000010214","volume":"97","author":"P Golabi","year":"2018","unstructured":"Golabi P, Otgonsuren M, de Avila L, Sayiner M, Rafiq N, Younossi ZM. Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD). Medicine (Baltimore). 2018;97(13): e0214.","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"1114_CR10","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/hep.27368","volume":"61","author":"M Ekstedt","year":"2015","unstructured":"Ekstedt M, Hagstr\u00f6m H, Nasr P, Fredrikson M, St\u00e5l P, Kechagias S, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61(5):1547\u201354.","journal-title":"Hepatology"},{"issue":"5","key":"1114_CR11","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/hep.29085","volume":"65","author":"PS Dulai","year":"2017","unstructured":"Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017;65(5):1557\u201365.","journal-title":"Hepatology"},{"issue":"7","key":"1114_CR12","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1007\/s10620-019-05986-9","volume":"65","author":"C Labenz","year":"2020","unstructured":"Labenz C, Huber Y, Michel M, Nagel M, Galle PR, Kostev K, et al. Impact of NAFLD on the incidence of cardiovascular diseases in a primary care population in Germany. Dig Dis Sci. 2020;65(7):2112\u20139.","journal-title":"Dig Dis Sci"},{"issue":"11","key":"1114_CR13","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1002\/hep4.1428","volume":"3","author":"C Labenz","year":"2019","unstructured":"Labenz C, Prochaska JH, Huber Y, Nagel M, Straub BK, Wild P, et al. Cardiovascular risk categories in patients with nonalcoholic fatty liver disease and the role of low-density lipoprotein cholesterol. Hepatol Commun. 2019;3(11):1472\u201381.","journal-title":"Hepatol Commun"},{"issue":"43","key":"1114_CR14","first-page":"719","volume":"117","author":"Y Huber","year":"2020","unstructured":"Huber Y, Labenz C, Michel M, W\u00f6rns MA, Galle PR, Kostev K, et al. Tumor incidence in patients with non-alcoholic fatty liver disease. Dtsch Arztebl Int. 2020;117(43):719\u201324.","journal-title":"Dtsch Arztebl Int"},{"issue":"7","key":"1114_CR15","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1053\/j.gastro.2020.02.020","volume":"158","author":"N Gehrke","year":"2020","unstructured":"Gehrke N, Schattenberg JM. Metabolic inflammation\u2014a role for hepatic inflammatory pathways as drivers of comorbidities in nonalcoholic fatty liver disease? Gastroenterology. 2020;158(7):1929-47.e6.","journal-title":"Gastroenterology"},{"issue":"4","key":"1114_CR16","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.jhep.2020.01.013","volume":"72","author":"CD Byrne","year":"2020","unstructured":"Byrne CD, Targher G. NAFLD as a driver of chronic kidney disease. J Hepatol. 2020;72(4):785\u2013801.","journal-title":"J Hepatol"},{"key":"1114_CR17","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.metabol.2017.11.003","volume":"79","author":"A Mantovani","year":"2018","unstructured":"Mantovani A, Zaza G, Byrne CD, Lonardo A, Zoppini G, Bonora E, et al. Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: a systematic review and meta-analysis. Metabolism. 2018;79:64\u201376.","journal-title":"Metabolism"},{"issue":"6","key":"1114_CR18","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/j.jhep.2017.08.024","volume":"67","author":"DH Sinn","year":"2017","unstructured":"Sinn DH, Kang D, Jang HR, Gu S, Cho SJ, Paik SW, et al. Development of chronic kidney disease in patients with non-alcoholic fatty liver disease: a cohort study. J Hepatol. 2017;67(6):1274\u201380.","journal-title":"J Hepatol"},{"issue":"1","key":"1114_CR19","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1136\/gutjnl-2020-323082","volume":"71","author":"A Mantovani","year":"2022","unstructured":"Mantovani A, Petracca G, Beatrice G, Csermely A, Lonardo A, Schattenberg JM, et al. Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. Gut. 2022;71(1):156\u201362.","journal-title":"Gut"},{"issue":"7","key":"1114_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158765","volume":"11","author":"NR Hill","year":"2016","unstructured":"Hill NR, Fatoba ST, Oke JL, Hirst JA, O\u2019Callaghan CA, Lasserson DS, et al. Global prevalence of chronic kidney disease\u2014a systematic review and meta-analysis. PLoS ONE. 2016;11(7): e0158765.","journal-title":"PLoS ONE"},{"issue":"10","key":"1114_CR21","doi-asserted-by":"publisher","first-page":"459","DOI":"10.5414\/CP203320","volume":"56","author":"W Rathmann","year":"2018","unstructured":"Rathmann W, Bongaerts B, Carius HJ, Kruppert S, Kostev K. Basic characteristics and representativeness of the German Disease Analyzer database. Int J Clin Pharmacol Ther. 2018;56(10):459\u201366.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"7","key":"1114_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001680","volume":"11","author":"G Musso","year":"2014","unstructured":"Musso G, Gambino R, Tabibian JH, Ekstedt M, Kechagias S, Hamaguchi M, et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med. 2014;11(7): e1001680.","journal-title":"PLoS Med"},{"issue":"4","key":"1114_CR23","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.metabol.2007.11.022","volume":"57","author":"Y Chang","year":"2008","unstructured":"Chang Y, Ryu S, Sung E, Woo HY, Oh E, Cha K, et al. Nonalcoholic fatty liver disease predicts chronic kidney disease in nonhypertensive and nondiabetic Korean men. Metabolism. 2008;57(4):569\u201376.","journal-title":"Metabolism"},{"issue":"10290","key":"1114_CR24","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","volume":"397","author":"EE Powell","year":"2021","unstructured":"Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397(10290):2212\u201324.","journal-title":"Lancet"},{"issue":"7","key":"1114_CR25","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S2468-1253(21)00020-0","volume":"6","author":"G Targher","year":"2021","unstructured":"Targher G, Tilg H, Byrne CD. Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. Lancet Gastroenterol Hepatol. 2021;6(7):578\u201388.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"1114_CR26","first-page":"194","volume":"15","author":"DV Garbuzenko","year":"2022","unstructured":"Garbuzenko DV. Pathophysiological mechanisms of cardiovascular disorders in non-alcoholic fatty liver disease. Gastroenterol Hepatol Bed Bench. 2022;15(3):194\u2013203.","journal-title":"Gastroenterol Hepatol Bed Bench"},{"issue":"10","key":"1114_CR27","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.molmed.2015.08.005","volume":"21","author":"G Musso","year":"2015","unstructured":"Musso G, Cassader M, Cohney S, Pinach S, Saba F, Gambino R. Emerging liver\u2013kidney interactions in nonalcoholic fatty liver disease. Trends Mol Med. 2015;21(10):645\u201362.","journal-title":"Trends Mol Med"},{"issue":"4","key":"1114_CR28","doi-asserted-by":"publisher","first-page":"562","DOI":"10.3390\/ijms17040562","volume":"17","author":"M Marcuccilli","year":"2016","unstructured":"Marcuccilli M, Chonchol M. NAFLD and chronic kidney disease. Int J Mol Sci. 2016;17(4):562.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"1114_CR29","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S2213-8587(14)70065-8","volume":"2","author":"AP de Vries","year":"2014","unstructured":"de Vries AP, Ruggenenti P, Ruan XZ, Praga M, Cruzado JM, Bajema IM, et al. Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease. Lancet Diabetes Endocrinol. 2014;2(5):417\u201326.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"1114_CR30","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1681\/ASN.2009080820","volume":"21","author":"JH Ix","year":"2010","unstructured":"Ix JH, Sharma K. Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPK. J Am Soc Nephrol. 2010;21(3):406\u201312.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"1114_CR31","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.bbrc.2006.09.071","volume":"350","author":"ST Mathews","year":"2006","unstructured":"Mathews ST, Rakhade S, Zhou X, Parker GC, Coscina DV, Grunberger G. Fetuin-null mice are protected against obesity and insulin resistance associated with aging. Biochem Biophys Res Commun. 2006;350(2):437\u201343.","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"1114_CR32","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1053\/j.ajkd.2014.05.019","volume":"64","author":"G Targher","year":"2014","unstructured":"Targher G, Chonchol MB, Byrne CD. CKD and nonalcoholic fatty liver disease. Am J Kidney Dis. 2014;64(4):638\u201352.","journal-title":"Am J Kidney Dis"},{"key":"1114_CR33","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/587140","volume":"2013","author":"T Hirata","year":"2013","unstructured":"Hirata T, Tomita K, Kawai T, Yokoyama H, Shimada A, Kikuchi M, et al. Effect of telmisartan or losartan for treatment of nonalcoholic fatty liver disease: fatty liver protection trial by telmisartan or Losartan Study (FANTASY). Int J Endocrinol. 2013;2013: 587140.","journal-title":"Int J Endocrinol"},{"issue":"9\u201310","key":"1114_CR34","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s00508-014-0661-y","volume":"127","author":"L Orlic","year":"2015","unstructured":"Orlic L, Mikolasevic I, Lukenda V, Anic K, Jelic I, Racki S. Nonalcoholic fatty liver disease and the renin\u2013angiotensin system blockers in the patients with chronic kidney disease. Wien Klin Wochenschr. 2015;127(9\u201310):355\u201362.","journal-title":"Wien Klin Wochenschr"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-023-01114-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-023-01114-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-023-01114-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,16]],"date-time":"2023-04-16T23:47:48Z","timestamp":1681688868000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-023-01114-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,17]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1114"],"URL":"https:\/\/doi.org\/10.1186\/s40001-023-01114-6","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,17]]},"assertion":[{"value":"4 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The \"Disease Analyzer\" database, used for analysis, contains anonymized electronic patient records. Patient data were analyzed in aggregated form without individual data being available. An individual consent form was not obtained following national and European legislation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Patient data were analyzed in aggregated form without individual health data being available. Individual informed consent was therefore not obtained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"153"}}